Exchange: NYSE·Updated 07:30 PM EDT
CRL logo

CRL Charles River Laboratories International Inc.

$301.79
$3.79
(1.27%)
Today
Closed $301.79
$0.00
(0.00%)
After Hours
EarningsNov 4
Mkt Cap$14.23B
Vol679,856.00

About CRL

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The Discovery and Safety Assessment segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.
64

Bullish Sentiment

How do you feel about CRL?

KryptonResearch14
$CRL Four firms raised targets on Charles River Labs Friday, after Thursday's Investor Day: Baird to 334 from 291, RBC to 322 from 282, Barclays to 330 from 300, and Mizuho to 295 from 264 (targets via MarketBeat). They are all really pricing the same slide: the 2026 outlook. Revenue reaffirmed at about 3.9 billion, EPS guide lifted to 11.45 against an 11.33 consensus, and first-ever 2030 growth targets. The stock jumped about 5 percent Thursday. The pushback is already on the tape: a Seeking Alpha note says the Investor Day numbers are fully priced in. Friday's cluster looks like catch-up, not leadership.

Advertisement|Remove ads.